國立虎尾科技大學 |

Ketamine for treatment-resistant depression = the first decade of progress /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Ketamine for treatment-resistant depression/ edited by Sanjay J. Mathew, Carlos A. Zarate, Jr.
其他題名:	the first decade of progress /
其他作者:	Mathew, Sanjay J.
出版者:	Cham :Springer International Publishing : : 2016.,
面頁冊數:	xix, 155 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Ketamine - Therapeutic use. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-42925-0
ISBN:	9783319429250

Ketamine for treatment-resistant depression = the first decade of progress /
Ketamine for treatment-resistant depressionthe first decade of progress /[electronic resource] :edited by Sanjay J. Mathew, Carlos A. Zarate, Jr. - Cham :Springer International Publishing :2016. - xix, 155 p. :ill., digital ;24 cm.

1. History of Ketamine Use and its Clinical Indications -- 2. Basic and Clinical Pharmacology of Ketamine -- 3. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders -- 4. Ketamine and Suicidality -- 5. Ketamine: Safety, Tolerability, and Impact on Neurocognition -- 6. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Pre-Clinical Studies -- 7. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies -- 8. Ketamine and Electroconvulsive Therapy -- 9. Beyond Depressive Disorders: Emerging Data for the Use of Ketamine in OCD, PTSD, and Alcohol/Substance Use Disorders.

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation "ketamine-like" fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine's psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine's rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine's rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

ISBN: 9783319429250

Standard No.: 10.1007/978-3-319-42925-0doiSubjects--Topical Terms:

1115876
Ketamine
--Therapeutic use.

LC Class. No.: RD86.K4

Dewey Class. No.: 615.781

Ketamine for treatment-resistant depression = the first decade of progress /
LDR:03771nam a2200313 a 4500 001 868336
003 DE-He213
005 20161130075614.0
006 m d
007 cr nn 008maaau
008 170720s2016 gw s 0 eng d
020 $a 9783319429250 $q (electronic bk.)
020 $a 9783319429236 $q (paper)
024 7 $a 10.1007/978-3-319-42925-0 $2 doi
035 $a 978-3-319-42925-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RD86.K4
072 7 $a MMGW $2 bicssc
072 7 $a MED105020 $2 bisacsh
082 0 4 $a 615.781 $2 23
090 $a RD86.K4 $b K43 2016
245 0 0 $a Ketamine for treatment-resistant depression $h [electronic resource] : $b the first decade of progress / $c edited by Sanjay J. Mathew, Carlos A. Zarate, Jr.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2016.
300 $a xix, 155 p. : $b ill., digital ; $c 24 cm.
505 0 $a 1. History of Ketamine Use and its Clinical Indications -- 2. Basic and Clinical Pharmacology of Ketamine -- 3. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders -- 4. Ketamine and Suicidality -- 5. Ketamine: Safety, Tolerability, and Impact on Neurocognition -- 6. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Pre-Clinical Studies -- 7. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies -- 8. Ketamine and Electroconvulsive Therapy -- 9. Beyond Depressive Disorders: Emerging Data for the Use of Ketamine in OCD, PTSD, and Alcohol/Substance Use Disorders.
520 $a This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation "ketamine-like" fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine's psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine's rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine's rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.
650 0 $a Ketamine $x Therapeutic use. $3 1115876
650 0 $a Medicine. $3 644133
650 0 $a Psychopharmacology. $3 644799
650 1 4 $a Medicine & Public Health. $3 593949
700 1 $a Mathew, Sanjay J. $3 1115875
700 1 $a Zarate, Carlos A. $3 897799
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-42925-0
950 $a Medicine (Springer-11650)